David Green tells MassDevice.com about the decision to split Harvard Bioscience and Harvard Apparatus Regenerative Technology, his choice to move over to the new entity and why regenerative technologies are poised to transform medicine.
Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with MassDevice.com, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.
Boston Millennia's managing general partner Dana Callow discusses the 11-year journey to bring CardioMEMs implantable heart monitor to market and what his venture capital firm sees for the future of medtech investment.
Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
TriVascular Technologies updates on its Ovation Prime aortic stent graft recall, warning that the company may take a hit as it loses some product from its inventory.
California medtech maker TriVascular Technologies (NSDQ:TRIV) issued an update today on the recall of certain of its Ovation Prime aortic stent grafts, advising that the measure may drag down full-year revenues.
Here's a look at some of the top legal news stories for medical device companies this week: Medigus raises $5.6M, touts clinical results for acid reflux device; Funding: InSightec raises $12.5M from Chinese backers; Corindus raises $26.6M for vascular robot; Intrinsic Therapeutics raises $17.2M for spinal surgery devices
Vector is Children's Hospital Boston's blog about research and innovation in pediatric and adult medicine. We report and comment on medical innovations and advances – from bench to bedside – touching on scientific, business and policy issues. Our ranks include science writers, physicians, lab researchers, market analysts and others inside and outside the hospital.
By Bruce Zetter
By now, we have all seen a surfeit of articles on how to foster a culture of innovation in the workplace. Unfortunately, with our words, actions and tone of voice, most of us do just the opposite; we stifle innovation at every turn.
The most recent Boston Scientific mesh lawsuit, which cost the company $74 million, featured an internal email that may have made a major impact on the jury.
MASSDEVICE ON CALL — Medtech titan Boston Scientific's (NYSE:BSX) logged a major loss after winning a few rounds in the ongoing lawsuits over its vaginal sling implants, and the deciding factor may have been the revelation of an internal company email.